Antares Pharma, Inc. has reported positive results from a multi-centre phase II clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous ...

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX ...

Testosterone therapy costs vary widely depending on the formulation you use, with injections generally the most affordable and pellets the most expensive. Even if insurance covers your testosterone ...